Congenital diseases are disorders in a newborn due to certain genetic factors (and sometimes in association with the environment) that often results in malformations or underdeveloped organs. Congenital Heart Diseases (CHD) results in malformed or undeveloped heart that presents in a newborn with breathing and circulation disorders. According to Lancet medical journal, CHD caused death of 0.22 million individuals and newborns globally in the year 2010. CHD was earlier erroneously associated with premature births, the association has no direct correlation with all forms of CHD and is mainly one of the many factors that can cause it. The genetic factors causing CHD consist of chromosomal errors in fertilization and the following meiotic division, these include: large chromosomal defects in trisomal chromosomes; small chromosomal defects like microdeletion of long/short arm of chromosome and random/environmentally induced mutation of heart muscle cell proteins, or associated proteins etc. The environmental factors like rubella infections, thalidomide drugs, metals (lithium, lead, mercury, etc), chronic illness in the mother (systemic lupus, diabetes, phenylketonuria, etc). Embryological changes, hormonal changes in the mother and certain birth deficiencies can also cause CHD and other birth defects in children. Besides these, according to some medical research reports, maternal obesity increased the chances of CHD in newborns; obesity was shown to increase the risk of previously hidden genetic traits of CHD in the new born children of such obese mothers.
The treatment of CHD varies from case to case; genetic testing/screening is mandatory in case the doctor suspects a genetic cause for the disease, in developed countries this is done for all newborns. The next step would be surgery or drug treatment, again this depends upon the severity of the condition. In most cases CHD presents itself as serious conditions with high risk of complications, hence surgery is the most followed procedure. In certain disorders like ASD a pediatric surgeon may ask the parents of a CHD child to wait for the child’s growth as ASD is known to disappear gradually, a surgery is performed if ASD persists after the child’s growth. Certain cases also require multiple surgeries and stenting in order to restore a malformed tract in the lungs, etc. Drugs like diuretics are given to regulate vasoconstriction that alleviates deoxygenation and helps remove toxins from the body, besides reducing the heartbeat.
Market Analysis and Insights: Global Congenital Heart Diseases Market
The global Congenital Heart Diseases market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Congenital Heart Diseases market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Congenital Heart Diseases market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Congenital Heart Diseases market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Congenital Heart Diseases market.
Congenital Heart Diseases Breakdown Data by Type
Hypoplasia
Obstructive
Septal Defects
Congenital Heart Diseases Breakdown Data by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
Based on regional and country-level analysis, the Congenital Heart Diseases market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Congenital Heart Diseases market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Pfizer
Abbott Laboratories
Eli Lilly
Ranbaxy Pharmaceutical
The treatment of CHD varies from case to case; genetic testing/screening is mandatory in case the doctor suspects a genetic cause for the disease, in developed countries this is done for all newborns. The next step would be surgery or drug treatment, again this depends upon the severity of the condition. In most cases CHD presents itself as serious conditions with high risk of complications, hence surgery is the most followed procedure. In certain disorders like ASD a pediatric surgeon may ask the parents of a CHD child to wait for the child’s growth as ASD is known to disappear gradually, a surgery is performed if ASD persists after the child’s growth. Certain cases also require multiple surgeries and stenting in order to restore a malformed tract in the lungs, etc. Drugs like diuretics are given to regulate vasoconstriction that alleviates deoxygenation and helps remove toxins from the body, besides reducing the heartbeat.
Market Analysis and Insights: Global Congenital Heart Diseases Market
The global Congenital Heart Diseases market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Congenital Heart Diseases market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Congenital Heart Diseases market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Congenital Heart Diseases market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Congenital Heart Diseases market.
Congenital Heart Diseases Breakdown Data by Type
Hypoplasia
Obstructive
Septal Defects
Congenital Heart Diseases Breakdown Data by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
Based on regional and country-level analysis, the Congenital Heart Diseases market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Congenital Heart Diseases market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Pfizer
Abbott Laboratories
Eli Lilly
Ranbaxy Pharmaceutical
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Congenital Heart Diseases Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Hypoplasia
1.2.3 Obstructive
1.2.4 Septal Defects
1.3 Market by Application
1.3.1 Global Congenital Heart Diseases Market Share by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Congenital Heart Diseases Market Perspective (2015-2026)
2.2 Global Congenital Heart Diseases Growth Trends by Regions
2.2.1 Congenital Heart Diseases Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Congenital Heart Diseases Historic Market Share by Regions (2015-2020)
2.2.3 Congenital Heart Diseases Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Congenital Heart Diseases Players by Market Size
3.1.1 Global Top Congenital Heart Diseases Players by Revenue (2015-2020)
3.1.2 Global Congenital Heart Diseases Revenue Market Share by Players (2015-2020)
3.2 Global Congenital Heart Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Congenital Heart Diseases Revenue
3.4 Global Congenital Heart Diseases Market Concentration Ratio
3.4.1 Global Congenital Heart Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Congenital Heart Diseases Revenue in 2019
3.5 Key Players Congenital Heart Diseases Area Served
3.6 Key Players Congenital Heart Diseases Product Solution and Service
3.7 Date of Enter into Congenital Heart Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Congenital Heart Diseases Breakdown Data by Type (2015-2026)
4.1 Global Congenital Heart Diseases Historic Market Size by Type (2015-2020)
4.2 Global Congenital Heart Diseases Forecasted Market Size by Type (2021-2026)
5 Congenital Heart Diseases Breakdown Data by Application (2015-2026)
5.1 Global Congenital Heart Diseases Historic Market Size by Application (2015-2020)
5.2 Global Congenital Heart Diseases Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Congenital Heart Diseases Market Size (2015-2026)
6.2 North America Congenital Heart Diseases Market Size by Type (2015-2020)
6.3 North America Congenital Heart Diseases Market Size by Application (2015-2020)
6.4 North America Congenital Heart Diseases Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Congenital Heart Diseases Market Size (2015-2026)
7.2 Europe Congenital Heart Diseases Market Size by Type (2015-2020)
7.3 Europe Congenital Heart Diseases Market Size by Application (2015-2020)
7.4 Europe Congenital Heart Diseases Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Congenital Heart Diseases Market Size (2015-2026)
8.2 China Congenital Heart Diseases Market Size by Type (2015-2020)
8.3 China Congenital Heart Diseases Market Size by Application (2015-2020)
8.4 China Congenital Heart Diseases Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Congenital Heart Diseases Market Size (2015-2026)
9.2 Japan Congenital Heart Diseases Market Size by Type (2015-2020)
9.3 Japan Congenital Heart Diseases Market Size by Application (2015-2020)
9.4 Japan Congenital Heart Diseases Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Congenital Heart Diseases Market Size (2015-2026)
10.2 Southeast Asia Congenital Heart Diseases Market Size by Type (2015-2020)
10.3 Southeast Asia Congenital Heart Diseases Market Size by Application (2015-2020)
10.4 Southeast Asia Congenital Heart Diseases Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Congenital Heart Diseases Introduction
11.1.4 Pfizer Revenue in Congenital Heart Diseases Business (2015-2020))
11.1.5 Pfizer Recent Development
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Details
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Congenital Heart Diseases Introduction
11.2.4 Abbott Laboratories Revenue in Congenital Heart Diseases Business (2015-2020)
11.2.5 Abbott Laboratories Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Congenital Heart Diseases Introduction
11.3.4 Eli Lilly Revenue in Congenital Heart Diseases Business (2015-2020)
11.3.5 Eli Lilly Recent Development
11.4 Ranbaxy Pharmaceutical
11.4.1 Ranbaxy Pharmaceutical Company Details
11.4.2 Ranbaxy Pharmaceutical Business Overview
11.4.3 Ranbaxy Pharmaceutical Congenital Heart Diseases Introduction
11.4.4 Ranbaxy Pharmaceutical Revenue in Congenital Heart Diseases Business (2015-2020)
11.4.5 Ranbaxy Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Congenital Heart Diseases Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Hypoplasia
1.2.3 Obstructive
1.2.4 Septal Defects
1.3 Market by Application
1.3.1 Global Congenital Heart Diseases Market Share by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Congenital Heart Diseases Market Perspective (2015-2026)
2.2 Global Congenital Heart Diseases Growth Trends by Regions
2.2.1 Congenital Heart Diseases Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Congenital Heart Diseases Historic Market Share by Regions (2015-2020)
2.2.3 Congenital Heart Diseases Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Congenital Heart Diseases Players by Market Size
3.1.1 Global Top Congenital Heart Diseases Players by Revenue (2015-2020)
3.1.2 Global Congenital Heart Diseases Revenue Market Share by Players (2015-2020)
3.2 Global Congenital Heart Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Congenital Heart Diseases Revenue
3.4 Global Congenital Heart Diseases Market Concentration Ratio
3.4.1 Global Congenital Heart Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Congenital Heart Diseases Revenue in 2019
3.5 Key Players Congenital Heart Diseases Area Served
3.6 Key Players Congenital Heart Diseases Product Solution and Service
3.7 Date of Enter into Congenital Heart Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Congenital Heart Diseases Breakdown Data by Type (2015-2026)
4.1 Global Congenital Heart Diseases Historic Market Size by Type (2015-2020)
4.2 Global Congenital Heart Diseases Forecasted Market Size by Type (2021-2026)
5 Congenital Heart Diseases Breakdown Data by Application (2015-2026)
5.1 Global Congenital Heart Diseases Historic Market Size by Application (2015-2020)
5.2 Global Congenital Heart Diseases Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Congenital Heart Diseases Market Size (2015-2026)
6.2 North America Congenital Heart Diseases Market Size by Type (2015-2020)
6.3 North America Congenital Heart Diseases Market Size by Application (2015-2020)
6.4 North America Congenital Heart Diseases Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Congenital Heart Diseases Market Size (2015-2026)
7.2 Europe Congenital Heart Diseases Market Size by Type (2015-2020)
7.3 Europe Congenital Heart Diseases Market Size by Application (2015-2020)
7.4 Europe Congenital Heart Diseases Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Congenital Heart Diseases Market Size (2015-2026)
8.2 China Congenital Heart Diseases Market Size by Type (2015-2020)
8.3 China Congenital Heart Diseases Market Size by Application (2015-2020)
8.4 China Congenital Heart Diseases Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Congenital Heart Diseases Market Size (2015-2026)
9.2 Japan Congenital Heart Diseases Market Size by Type (2015-2020)
9.3 Japan Congenital Heart Diseases Market Size by Application (2015-2020)
9.4 Japan Congenital Heart Diseases Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Congenital Heart Diseases Market Size (2015-2026)
10.2 Southeast Asia Congenital Heart Diseases Market Size by Type (2015-2020)
10.3 Southeast Asia Congenital Heart Diseases Market Size by Application (2015-2020)
10.4 Southeast Asia Congenital Heart Diseases Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Congenital Heart Diseases Introduction
11.1.4 Pfizer Revenue in Congenital Heart Diseases Business (2015-2020))
11.1.5 Pfizer Recent Development
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Details
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Congenital Heart Diseases Introduction
11.2.4 Abbott Laboratories Revenue in Congenital Heart Diseases Business (2015-2020)
11.2.5 Abbott Laboratories Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Congenital Heart Diseases Introduction
11.3.4 Eli Lilly Revenue in Congenital Heart Diseases Business (2015-2020)
11.3.5 Eli Lilly Recent Development
11.4 Ranbaxy Pharmaceutical
11.4.1 Ranbaxy Pharmaceutical Company Details
11.4.2 Ranbaxy Pharmaceutical Business Overview
11.4.3 Ranbaxy Pharmaceutical Congenital Heart Diseases Introduction
11.4.4 Ranbaxy Pharmaceutical Revenue in Congenital Heart Diseases Business (2015-2020)
11.4.5 Ranbaxy Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
